Page 2 - Nasdaq Clrb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr. Levy to Provide Perspective on Iopofosine I 131’s Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia...

Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy...

StockNews.com upgraded shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) to a sell rating in a research report sent to investors on Thursday morning. Cellectar Biosciences Stock Performance NASDAQ CLRB opened at $2.77 on Thursday. The company has a market capitalization of $34.04 million, a P/E ratio of -0.85 and a beta of 1.10. Cellectar […]

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 800,100 shares, a decline of 7.2% from the October 31st total of 861,800 shares. Approximately 6.9% of the company’s shares are short sold. […]

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 664,100 shares, an increase of 37.7% from the September 15th total of 482,200 shares. Based on an average trading volume of 646,800 shares, […]